IXHL
Incannex Healthcare Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website incannex.com
- Employees(FY) -
- ISIN US45333F1093
Performance
-5.08%
1W
-21.86%
1M
-11.58%
3M
-51.16%
6M
-63.79%
YTD
-54.1%
1Y
Profile
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Norwest, Australia.
Technical Analysis of IXHL 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-02 03:48
- 2024-11-14 03:05
- 2024-10-23 19:30
- 2024-10-02 04:50
- 2024-09-30 04:01
- 2024-09-09 20:00
- 2024-09-08 20:00
- 2024-08-04 19:30
- 2024-07-29 19:30
- 2024-06-30 19:37
- 2024-06-26 19:34
- 2024-05-29 19:30
- 2024-05-06 19:30
- 2024-05-01 02:33
- 2024-04-15 20:00
Incannex Healthcare Inc. Quarterly Update, Q1 2024(Globenewswire)
- 2024-03-23 19:55
11 Best ASX Stocks To Buy Now(Insidermonkey)
- 2024-02-27 18:30
- 2024-02-15 18:30
- 2024-01-31 18:30
Clarion Clinics Open for Psychedelic-Assisted Treatments(Globenewswire)
- 2024-01-24 03:05
- 2024-01-17 19:22
- 2024-01-16 18:30
- 2023-12-21 03:05
- 2023-12-05 18:30
- 2023-11-29 00:40
- 2023-11-15 19:30
- 2023-09-07 19:30
- 2023-08-24 01:15
Incannex preparing psilocybin therapy FDA IND application(Yahoo Finance)
- 2023-08-23 19:30
- 2023-08-22 23:45
Incannex full steam ahead towards sleep apnoea trial(Yahoo Finance)
Page 1 of 4
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.